Sociedad Americana de Hirudoterapia

Hirudin and hirudin analogues as new anticoagulant agents

Research article published in Current opinion in hematology (1995)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosEnsayos clínicosPineo G, Hull R · Current opinion in hematology, 1995

Abstract

Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation. As opposed to unfractionated heparin, hirudin and hirulog effectively suppress clot-bound thrombin, making these agents of particular interest in the treatment of arterial thrombosis, for example, following thrombolysis or percutaneous transthoracic angioplasty. The recent data derived from clinical trials supporting the use of hirudin and hirulog in the prevention and treatment of thrombotic diseases are reviewed here.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAngina, UnstableAnticoagulantsCardiovascular DiseasesClinical Trials as TopicHirudin TherapyHirudinsHumansMyocardial InfarctionPeptide FragmentsRecombinant ProteinsThrombolytic Therapy

Resumen

Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation.

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

Hirudin and hirudin analogues as new anticoagulant agents.

Pineo G, Hull R · Current opinion in hematology, 1995

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Hirudin and hirudin analogues as new anticoagulant agents | ASH